199 related articles for article (PubMed ID: 12169691)
1. The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1.
Zhou MI; Wang H; Ross JJ; Kuzmin I; Xu C; Cohen HT
J Biol Chem; 2002 Oct; 277(42):39887-98. PubMed ID: 12169691
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 protein occurs through plant homeodomains and is VHL mutation dependent.
Zhou MI; Wang H; Foy RL; Ross JJ; Cohen HT
Cancer Res; 2004 Feb; 64(4):1278-86. PubMed ID: 14973063
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.
Li Z; Na X; Wang D; Schoen SR; Messing EM; Wu G
J Biol Chem; 2002 Feb; 277(7):4656-62. PubMed ID: 11739384
[TBL] [Abstract][Full Text] [Related]
4. Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells.
Galbán S; Martindale JL; Mazan-Mamczarz K; López de Silanes I; Fan J; Wang W; Decker J; Gorospe M
Mol Cell Biol; 2003 Oct; 23(20):7083-95. PubMed ID: 14517280
[TBL] [Abstract][Full Text] [Related]
5. von Hippel-Lindau partner Jade-1 is a transcriptional co-activator associated with histone acetyltransferase activity.
Panchenko MV; Zhou MI; Cohen HT
J Biol Chem; 2004 Dec; 279(53):56032-41. PubMed ID: 15502158
[TBL] [Abstract][Full Text] [Related]
6. Jade-1, a candidate renal tumor suppressor that promotes apoptosis.
Zhou MI; Foy RL; Chitalia VC; Zhao J; Panchenko MV; Wang H; Cohen HT
Proc Natl Acad Sci U S A; 2005 Aug; 102(31):11035-40. PubMed ID: 16046545
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product.
Tsuchiya H; Iseda T; Hino O
Cancer Res; 1996 Jul; 56(13):2881-5. PubMed ID: 8674032
[TBL] [Abstract][Full Text] [Related]
8. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
9. Role of nuclear and cytoplasmic localization in the tumour-suppressor activity of the von Hippel-Lindau protein.
Lewis MD; Roberts BJ
Oncogene; 2003 Jun; 22(26):3992-7. PubMed ID: 12821933
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
Tanimoto K; Makino Y; Pereira T; Poellinger L
EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113
[TBL] [Abstract][Full Text] [Related]
11. Tumour suppression by the human von Hippel-Lindau gene product.
Iliopoulos O; Kibel A; Gray S; Kaelin WG
Nat Med; 1995 Aug; 1(8):822-6. PubMed ID: 7585187
[TBL] [Abstract][Full Text] [Related]
12. The von Hippel-Lindau tumor suppressor targets to mitochondria.
Shiao YH; Resau JH; Nagashima K; Anderson LM; Ramakrishna G
Cancer Res; 2000 Jun; 60(11):2816-9. PubMed ID: 10850420
[TBL] [Abstract][Full Text] [Related]
13. Molecular cloning and characterization of the von Hippel-Lindau-like protein.
Qi H; Gervais ML; Li W; DeCaprio JA; Challis JR; Ohh M
Mol Cancer Res; 2004 Jan; 2(1):43-52. PubMed ID: 14757845
[TBL] [Abstract][Full Text] [Related]
14. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density.
Lee S; Chen DY; Humphrey JS; Gnarra JR; Linehan WM; Klausner RD
Proc Natl Acad Sci U S A; 1996 Mar; 93(5):1770-5. PubMed ID: 8700833
[TBL] [Abstract][Full Text] [Related]
15. The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways.
Devarajan P; De Leon M; Talasazan F; Schoenfeld AR; Davidowitz EJ; Burk RD
J Biol Chem; 2001 Nov; 276(44):40599-605. PubMed ID: 11514546
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells.
Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M
Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066
[TBL] [Abstract][Full Text] [Related]
17. Polycystin-1 regulates the stability and ubiquitination of transcription factor Jade-1.
Foy RL; Chitalia VC; Panchenko MV; Zeng L; Lopez D; Lee JW; Rana SV; Boletta A; Qian F; Tsiokas L; Piontek KB; Germino GG; Zhou MI; Cohen HT
Hum Mol Genet; 2012 Dec; 21(26):5456-71. PubMed ID: 23001567
[TBL] [Abstract][Full Text] [Related]
18. Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma.
Zeng L; Bai M; Mittal AK; El-Jouni W; Zhou J; Cohen DM; Zhou MI; Cohen HT
Cancer Res; 2013 Sep; 73(17):5371-80. PubMed ID: 23824745
[TBL] [Abstract][Full Text] [Related]
19. Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region.
Schoenfeld AR; Davidowitz EJ; Burk RD
Int J Cancer; 2001 Feb; 91(4):457-67. PubMed ID: 11251966
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
Knebelmann B; Ananth S; Cohen HT; Sukhatme VP
Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
